GLP-1 Drugs

The FDA recently approved semaglutide (Wegovy) for preventing serious heart conditions in some people, but questions remain about how it works

A plethora of new weight-loss drugs are now available in the U.S., but they aren’t necessarily the same. Here’s a guide to the latest GLP-1 receptor agonists

Popular weight-loss and diabetes drugs, such as Ozempic and Wegovy, target metabolic pathways that gut microbes and food molecules already play a key role in regulating

The world has launched into an era of injectables not just to treat obesity but to manage weight. Is that all good news?

Ozempic and similar drugs are ushering in a new era of weight management and obesity treatments, and researchers are racing to understand their impact

The active ingredient in Wegovy and Ozempic reduced the risk of heart attacks and strokes in a large trial of people with cardiovascular disease who were considered overweight or had obesity, but the cost and side effects remain barriers

Recent studies evaluate risks associated with drugs such as Wegovy and Mounjaro

Insurance plans could cover blockbuster weight-loss medications such as Wegovy and Ozempic, but the benefits may not be accessible to everyone

Clinical-trial data suggest that semaglutide, sold under the name Wegovy, slashed risk of heart attacks and other cardiovascular incidents in a trial

Drugs such as Wegovy and Ozempic might help people tackle substance abuse as well as shed pounds.

Limited data on adults age 60 and older raise questions on whether high-priced weight-loss drugs will really help with lowering rates of chronic illness and disability

Ozempic and similar medications may target brain circuitry involved in addiction as well as appetite control